Diagnosis and Management of Hair Loss

Clinical Examination and History

The British Association of Dermatologists recommends a focused clinical examination to distinguish between alopecia areata and other causes of hair loss, such as telogen effluvium or androgenetic alopecia, by examining the scalp for patchy versus diffuse hair loss 1, 2, 3
Exclamation mark hairs are pathognomonic for alopecia areata and can be identified through dermoscopy, which is a valuable diagnostic tool according to the British Journal of Dermatology 1, 3
A thorough history should include the duration of hair loss, with onset <1 year suggesting a better prognosis with potential spontaneous remission in 34-50% of cases, as stated by the British Journal of Dermatology 3, 2
Medication history should be taken, specifically asking about chemotherapy or other drugs that cause anagen effluvium, as recommended by the British Journal of Dermatology 1, 3

Laboratory Testing

The British Association of Dermatologists states that investigations are unnecessary in most cases of alopecia areata when the diagnosis is clinically evident, unless the diagnosis is uncertain or there are signs of underlying conditions such as iron deficiency or thyroid disease 1, 4, 5, 6
Targeted laboratory tests, such as fungal culture, skin biopsy, serology for lupus erythematosus, and serology for syphilis, should only be performed when the diagnosis is uncertain or when there are signs of underlying conditions, as recommended by the British Journal of Dermatology 1, 4, 5, 2
Serum ferritin, vitamin D level, and serum zinc should be checked if iron deficiency, vitamin D deficiency, or zinc deficiency is suspected, with optimal ferritin ≥60 ng/mL needed for hair growth, as stated by the British Journal of Dermatology and Praxis Medical Insights 1, 6, 2
TSH and free T4 should be checked for thyroid disease, which commonly causes hair loss, as recommended by Praxis Medical Insights 2
Total testosterone, free testosterone, and SHBG should only be checked if signs of androgen excess are present, such as acne, hirsutism, or irregular periods, as recommended by Praxis Medical Insights 2

Management and Differential Diagnosis

The British Association of Dermatologists recommends watchful waiting with reassurance as a legitimate option for limited patchy hair loss of short duration, as 34-50% of patients recover within one year without treatment 3, 6, 2
Patients should be counseled that regrowth cannot be expected within 3 months of any individual patch development, and that no treatment alters the long-term course of alopecia areata, though some can induce temporary hair regrowth, as stated by the British Journal of Dermatology 4, 5, 6, 1
Trichotillomania, tinea capitis, telogen effluvium, and androgenetic alopecia should be considered in the differential diagnosis, with specific characteristics and diagnostic criteria for each condition, as recommended by the British Journal of Dermatology and Praxis Medical Insights 1, 3, 2

Hair Loss Treatment and Management

Diagnostic Approach and Treatment Options

The American Academy of Dermatology recommends topical minoxidil 2% solution twice daily as the first-line treatment for androgenetic alopecia in women, which arrests progression rather than stimulates regrowth 7
For limited alopecia areata, watchful waiting with reassurance is a legitimate first option, as 34-50% recover within one year without treatment, according to the British Association of Dermatologists 8
Intralesional corticosteroids, such as triamcinolone acetonide 5-10 mg/mL, can be used for limited alopecia areata if treatment is desired, with a strength of recommendation B III, as suggested by the British Journal of Dermatology 9
Contact immunotherapy is the best-documented treatment for extensive alopecia areata, but has a less than 50% response rate and requires multiple hospital visits over months, with a strength of recommendation B II-ii, according to the British Journal of Dermatology 9
Wigs can provide immediate cosmetic benefit for women with extensive alopecia areata, as recommended by the British Association of Dermatologists 9, 10
Platelet-rich plasma (PRP) injections show promise for androgenetic alopecia, with increased hair density in clinical trials, although repeated treatments every 6 months are required, as reported in Periodontology 2000 7, 11

Treatments to Avoid

The British Association of Dermatologists advises against using potent topical corticosteroids for alopecia areata due to lack of convincing evidence of effectiveness 8
Systemic corticosteroids or PUVA for alopecia areata are not recommended due to potentially serious side-effects and inadequate efficacy evidence, as stated by the British Journal of Dermatology 8
Oral zinc or isoprinosine are ineffective in controlled trials for alopecia areata, according to the British Journal of Dermatology 9

Evaluation and Management of New Onset Hair Loss

Initial Clinical Assessment

The British Journal of Dermatology suggests that diffuse thinning over the central scalp with preserved frontal hairline is indicative of androgenetic alopecia, while discrete patches indicate alopecia areata 12
The presence of exclamation mark hairs, which are short broken hairs at patch margins, is pathognomonic for alopecia areata and can be identified with dermoscopy 12
Scalp inflammation or scaling suggests tinea capitis or early scarring alopecia rather than androgenetic alopecia or alopecia areata, according to the British Journal of Dermatology 12, 13
A family history of alopecia areata is present in 20% of cases, as reported by the British Journal of Dermatology 12, 13

Laboratory Testing Strategy

The British Journal of Dermatology recommends that investigations are unnecessary in most cases when the diagnosis is clinically evident 13
Fungal culture is only necessary if tinea capitis is suspected, as indicated by scalp inflammation or scaling, according to the British Journal of Dermatology 13, 14
Skin biopsy is reserved for uncertain diagnosis or suspected scarring alopecia, as suggested by the British Journal of Dermatology 13, 14

Treatment Algorithm Based on Diagnosis

For limited patchy alopecia areata, watchful waiting with reassurance is a legitimate first option, as 34-50% recover within one year without treatment, according to the British Journal of Dermatology 12
Platelet-rich plasma (PRP) injections show promise with increased hair density, requiring treatments every 6 months, as reported by Periodontology 2000 15

Common Pitfalls

Ordering extensive autoimmune panels in straightforward alopecia areata cases is unnecessary, as stated by the British Journal of Dermatology 14
Failing to consider trichotillomania, where broken hairs remain firmly anchored, is a common pitfall, according to the British Journal of Dermatology 12, 13

Hair Loss Treatment Guidelines

First-Line Treatment Protocol

The American Academy of Dermatology recommends initiating combination therapy with oral finasteride 1 mg daily and topical minoxidil 5% solution twice daily for optimal results in treating androgenetic alopecia, as this approach has been proven to halt progression and stimulate regrowth in clinical trials 16
Treatment with finasteride and minoxidil must be continuous to maintain results, as stopping treatment will result in hair loss resuming, according to the Periodontology 2000 guideline 16

Adjunctive Treatment Options

Platelet-rich plasma (PRP) injections can be considered as adjunctive therapy, with a protocol of 3-5 sessions at 1-month intervals, then maintenance every 6 months, as clinical trials have shown increased hair density and hair count 16
The mechanism of PRP injections induces proliferation of dermal papilla, increases perifollicular vascularization, and accelerates telogen-to-anagen transition, with higher platelet concentrations showing greater effects on hair density and follicle diameter 16

Clinical Signs

The presence of patchy hair loss with “exclamation‑mark” hairs on dermoscopy confirms alopecia areata. 17
Diffuse shedding over the entire scalp is characteristic of telogen effluvium and is often precipitated by stress, nutritional deficiency, or recent illness. 17
Scalp inflammation or scaling suggests tinea capitis or a scarring alopecia and warrants fungal culture or biopsy for confirmation. 17

Laboratory Evaluation

When alopecia areata is clinically obvious (patchy loss with exclamation‑mark hairs), no routine laboratory testing is required. 17

Management of Limited‑Duration Alopecia Areata

Watchful Waiting

For limited patchy alopecia areata of less than one year’s duration, observation is advised because 34 %–50 % of patients experience spontaneous regrowth within one year without any therapy. [18][19]
Patients should be counseled that visible regrowth is unlikely within the first three months after a new patch appears. [18][19]
No current treatment has been proven to modify the long‑term natural history of alopecia areata, although some interventions may produce temporary hair regrowth. [18][19]

Pharmacologic Options (Limited Patches)

Very potent topical corticosteroids (e.g., clobetasol propionate 0.05 % foam) have limited supporting evidence but may be trialed in isolated patches. [18][19]

Supportive Measures for Extensive Disease

Wearing wigs offers immediate cosmetic benefit and is often the most practical solution for patients with extensive, longstanding alopecia areata. 18

Psychological Impact and Referral

Hair loss can have a profound psychological effect; patients who become withdrawn, experience low self‑esteem, or encounter work/social difficulties should be considered for referral to mental‑health services. [17][18]

Diagnostic Pitfalls to Avoid

Trichotillomania should not be mistaken for alopecia areata: in trichotillomania, broken hairs remain firmly anchored in the anagen phase, whereas alopecia areata shows exclamation‑mark hairs. 17
Routine extensive autoimmune panels are unnecessary for straightforward alopecia areata, as the modest increase in autoimmune disease prevalence does not justify routine screening. 17
The psychological burden of hair loss must not be overlooked; addressing emotional distress is as essential as treating the physical condition. [17][18]

Management of Alopecia Areata in Dialysis Patients

Pharmacologic Treatment

Intralesional triamcinolone acetonide (5–10 mg/mL) is recommended as first‑line therapy for limited patchy alopecia areata in dialysis patients, offering the strongest evidence of efficacy (Strength of recommendation B, Quality III). 20

Non‑Pharmacologic Support

Use of wigs provides immediate cosmetic improvement and is often the most practical solution for extensive, longstanding alopecia areata in dialysis patients. 20

Therapeutic Interventions for Alopecia Areata with Evidence

Intralesional Corticosteroid Therapy

In patients with limited patchy alopecia areata (≤ 5 patches, each ≤ 3 cm in diameter), intralesional triamcinolone acetonide 5–10 mg/mL injected 0.05–0.1 mL just beneath the dermis produces a regrowth tuft of ≈ 0.5 cm diameter; 62 % achieve full regrowth after monthly injections, with the effect persisting for about 9 months. The main drawback is patient discomfort. Strength of recommendation B, quality III. 21

Contact Immunotherapy for Extensive Disease

For patients with extensive alopecia areata (> 50 % scalp involvement), contact immunotherapy with diphenylcyclopropenone (DPCP) is the best‑documented treatment, achieving a response in < 50 % of appropriately selected candidates. The regimen requires multiple hospital visits over several months and should be administered by a dermatologist experienced in immunotherapy. Strength of recommendation B, quality II‑ii. 21

Evaluation and Management of Hair Loss in Adolescents

Epidemiology and Prognosis

In adolescents with alopecia areata, spontaneous remission occurs in 34–50 % of patients within one year of onset, indicating a favorable short‑term prognosis for many cases. American Academy of Pediatrics 22
A family history of alopecia areata is present in about 20 % of affected adolescents, supporting a hereditary component. British Association of Dermatologists 23

Diagnostic Assessment

Clinical pattern: Discrete patches with exclamation‑mark hairs are diagnostic of alopecia areata, whereas diffuse central thinning with a preserved frontal hairline suggests androgenetic alopecia. British Association of Dermatologists 23
Dermoscopy: The presence of yellow dots and exclamation‑mark hairs is pathognomonic for alopecia areata and can obviate the need for scalp biopsy. British Association of Dermatologists 23
Tanner stage evaluation and screening for signs of androgen excess (e.g., acne, hirsutism) help identify underlying polycystic ovary syndrome as a potential contributor. American Academy of Pediatrics 22
Hair‑care practices: Tight hairstyles raise suspicion for traction alopecia, while compulsive hair‑pulling behaviors suggest trichotillomania. British Association of Dermatologists 23

Laboratory Testing

Targeted testing is only indicated when the clinical picture is atypical, the diagnosis is uncertain, or systemic disease signs are present; routine labs are unnecessary in classic alopecia areata. British Association of Dermatologists 23
Fungal culture should be performed only if scalp inflammation or scaling suggests tinea capitis. British Association of Dermatologists 23
Extensive autoimmune panels are not recommended for straightforward alopecia areata because the modest increase in autoimmune disease prevalence does not justify routine screening. British Association of Dermatologists 23

Management

Limited Patchy Alopecia Areata (≤5 patches, each ≤3 cm)

Watchful waiting is the first‑line approach; 34–50 % of patients experience regrowth within one year without treatment. British Association of Dermatologists 23
If treatment is desired, intralesional triamcinolone acetonide 5–10 mg/mL (0.05–0.1 mL per injection) administered monthly yields regrowth in ≈62 % of patients.
- Strength of recommendation: B
- Quality of evidence: III – British Association of Dermatologists 23

Extensive Alopecia Areata (>50 % scalp involvement)

Contact immunotherapy with diphenylcyclopropenone (DPCP) achieves a therapeutic response in <50 % of appropriately selected patients and requires multiple clinic visits over several months.
- Strength of recommendation: B
- Quality of evidence: II‑ii – British Association of Dermatologists 23
Wigs provide immediate cosmetic benefit and are often the most practical solution for extensive, longstanding disease.

Androgenetic Alopecia

Topical minoxidil 2 % solution applied twice daily is the first‑line therapy for adolescent females, although systematic data in this age group are limited.

Telogen Effluvium

Removal of the precipitating trigger (e.g., stress, nutritional deficiency, illness) leads to spontaneous remission in up to 80 % of cases with short duration (<1 year).

Tinea Capitis

Systemic oral antifungal therapy is required; fungal culture must be obtained before initiating treatment.

Pitfalls and Contraindications

Do not confuse trichotillomania with alopecia areata: trichotillomania shows broken hairs that remain firmly anchored in anagen, whereas alopecia areata displays exclamation‑mark hairs. British Association of Dermatologists 23
Potent topical corticosteroids lack convincing efficacy for alopecia areata and should be avoided. British Association of Dermatologists 23
Systemic corticosteroids and PUVA have potentially serious adverse effects and insufficient efficacy evidence; they are not recommended. British Association of Dermatologists 23
If the adolescent cannot tolerate the scalp examination, the exam should be paused and rescheduled to avoid distress. American Academy of Pediatrics 22

Referral Recommendations

Refer to dermatology when the diagnosis remains uncertain despite clinical and dermoscopic evaluation.
Referral is indicated for extensive alopecia areata requiring contact immunotherapy.
Suspected scarring alopecia or treatment‑resistant cases should be evaluated by a dermatologist.
A scalp biopsy is warranted when the diagnosis cannot be clarified by non‑invasive methods. British Association of Dermatologists 23

Evaluation and Management of Alopecia Areata in Older Adults with Unintentional Weight Loss

Diagnostic Work‑up

Clinical diagnosis of alopecia areata generally does not require additional laboratory investigations when characteristic findings (exclamation‑mark hairs, yellow dots on dermoscopy) are present; routine testing adds little value (British Journal of Dermatology, 2012) 24.
Fungal culture of scalp scrapings should be performed only when inflammation or scaling suggests tinea capitis (British Journal of Dermatology, 2012) 24.
Skin biopsy is indicated solely when the diagnosis remains uncertain after clinical examination and dermoscopic assessment (British Journal of Dermatology, 2012) 24.
Serologic testing for systemic lupus erythematosus is warranted only if accompanying systemic features (e.g., arthralgia, photosensitivity, rash) are present (British Journal of Dermatology, 2012) 24.
Syphilis serology should be ordered only when risk factors for infection exist (British Journal of Dermatology, 2012) 24.
Routine extensive autoimmune panels are not recommended for straightforward alopecia areata because the modest increase in autoimmune disease prevalence does not justify screening (British Journal of Dermatology, 2012) 24.

Therapeutic Recommendations

Wigs provide immediate cosmetic benefit for patients with extensive or long‑standing alopecia areata (British Journal of Dermatology, 2012) 24.
No current therapy has been shown to modify the long‑term natural history of alopecia areata; treatments may induce temporary regrowth but do not alter disease course (British Journal of Dermatology, 2012) 24.

Psychological and Differential Diagnosis Considerations

Depression accounts for 11–16 % of unintentional weight‑loss cases in older adults, and alopecia can markedly affect quality of life; therefore, mental‑health assessment should be incorporated into the evaluation (British Journal of Dermatology, 2012) 24.
Trichotillomania must be distinguished from alopecia areata: trichotillomania shows firmly anchored broken hairs, whereas alopecia areata exhibits exclamation‑mark hairs (British Journal of Dermatology, 2012) 24.

Evidence‑Based Guidelines for Hair Loss in Adolescents

Diagnostic Evaluation

Targeted laboratory testing should be limited to cases with diagnostic uncertainty, atypical presentation, or systemic disease signs; routine extensive panels are unnecessary. 25
Fungal culture is indicated only when scalp inflammation or scaling suggests tinea capitis. 25
Scalp biopsy is reserved for uncertain diagnoses or suspected scarring alopecia. 25
Extensive autoimmune panels are not recommended for straightforward alopecia areata due to low yield. 25

Management of Specific Conditions

Limited Patchy Alopecia Areata (≤5 patches, each ≤3 cm)

Watchful waiting is first‑line; 34–50 % of patients experience spontaneous regrowth within one year. 25
Counsel patients that visible regrowth is unlikely within the first three months after a new patch appears. 25

Extensive Alopecia Areata (>50 % scalp involvement)

Wigs provide immediate cosmetic benefit and are often the most practical solution. 25

Telogen Effluvium

Identifying and removing the precipitating trigger leads to spontaneous remission in up to 80 % of cases with duration < 1 year. 25

Laboratory Findings

Serum zinc levels may be lower in alopecia areata patients, especially those with disease resistant for >6 months. 26

Treatments to Avoid

Potent topical corticosteroids lack convincing efficacy evidence for alopecia areata and should be avoided. 25
Systemic corticosteroids and PUVA have potentially serious adverse effects and insufficient efficacy evidence for alopecia areata; they should be avoided. 25
Oral zinc or isoprinosine have not demonstrated benefit in controlled trials for alopecia areata and should not be used. 25

Critical Pitfalls

Do not confuse trichotillomania with alopecia areata: trichotillomania shows broken hairs firmly anchored in anagen phase, whereas alopecia areata displays exclamation‑mark hairs. 25
Do not order extensive laboratory panels when clinical findings clearly indicate a specific hair‑loss diagnosis. 25

Psychosocial Considerations

Hair loss can profoundly affect self‑esteem, school performance, and social functioning in adolescents; referral to pediatric psychology is warranted when behavioral or emotional changes are noted. 25

Prognosis

No current treatment alters the long‑term natural history of alopecia areata; interventions may induce temporary regrowth but should not be presented as a cure. 25

Platelet‑Rich Plasma (PRP) Therapy for Androgenetic Alopecia

Evidence‑Based Recommendations

The 2025 Periodontology 2000 guideline reports that a regimen of 3–5 PRP injection sessions performed at 1‑month intervals, followed by maintenance injections every 6 months, leads to increased hair density in clinical trials for androgenetic alopecia【27】.
For adults with pattern hair loss who show an inadequate response to topical minoxidil after 6 months, the same guideline recommends adding PRP as an adjunctive therapy using the protocol described above【27】.
The strength of evidence for PRP is characterized as emerging clinical‑trial data, providing moderate support for its use but not yet qualifying it as a first‑line treatment【27】.

Laboratory Evaluation of Diffuse Hair Loss

Core Laboratory Panel

Serum ferritin measurement is the most critical laboratory test for diffuse hair loss because iron deficiency is the leading nutritional cause worldwide; evaluating ferritin helps identify patients who may benefit from iron repletion. 28

Zinc Assessment

Serum zinc concentrations are frequently lower in individuals with alopecia areata, especially in cases where the disease has persisted for more than six months, suggesting zinc deficiency may influence disease chronicity. 28